Skip to Content

'
Uday R Popat, M.D.

Present Title & Affiliation

N/A

Bio Statement

 

Dr. Uday Popat graduated from the Lokmanya Tilak Municipal Medical College in Bombay, India. He completed the residency and fellowship programs at institutions in the United Kingdom, India and the United States including Baylor College of Medicine and The University of Texas MD Anderson Cancer Center. He is currently Professor of Medicine in the department of Stem Cell Transplantation and Cellular Therapy at The University of Texas MD Anderson Cancer Center.

Research Interests

Myelofibrosis: Reduced intensity allogeneic transplantation(SCT) for myelofibrosis: This is a novel study, first protocol in this disease at MDACC and the largest single center study, which is still accruing patients. Our preliminary results are encouraging. If these hold over a period of time, this should become standard of care and establish allogeneic transplant as a viable, curative therapy. In a separate study we showed that long term remission was possible in patients with AML post MF after SCT. This finding has not been previously reported.

Multiple Sclerosis:  My previous study and current ongoing study at MDACC will go some way in establishing a role for autologous transplantation in this disease. Our study on allogeneic transplantation for patients with ALS was novel and although negative for clinical endpoints did show significant trafficking of donor hematopoietic stem cells to diseased areas in central nervous system.

Imapct of comorbidities on SCT: To identify patients most suitable for allo transplant and to identify the most suitable transplant strategy for patients with comorbidities.

Risk factors predicting stem cell mobilization failure.

Education & Training

Degree-Granting Education

2003 Royal College of Pathologists, London, United Kingdom, FRCPath, Hematology
1995 Royal College of Pathologists, London, United Kingdom, MRCPath, Hematology
1994 Royal College of Pathologists, London, United Kingdom, Dip RCPath, Hematology
1991 Royal College of Physicians, London, United Kingdom, MRCP, Internal Medicine
1988 University of Bombay, Lokmanya Tilak Municipal Medical College & Hospital, Bomabay, India, MD, Internal Medicine
1983 University of Bombay, Lokmanya Tilak Municipal Medical College & Hospital, Bombay, India, MB, BS, Med School

Postgraduate Training

1997-1999 Residency, Internal Medicine, Baylor College of Medicine, Houston, TX
1996-1997 Fellowship, Hematology and Medical Oncology, Baylor College of Medicine, Houston, TX
1995-1996 Fellowship, Bone Marrow Transplant, The University of Texas MD Anderson Cancer Center, Houston, TX
1994-1995 Fellowship, Bone Marrow Transplant, Royal Free Hospital and School of Medicine University of London, London, United Kingdom
1983-1988 Internship and Residency, Internal Medicine, Lokmanya Tilak Municipal Medical College and General Hospital, University of Bombay, Bombay, India

Board Certifications

1/2001 American Board of Internal Medicine, Medical Oncology
1/2001 American Board of Internal Medicine, Hematology
1/2000 American Board of Internal Medicine, Internal Medicine

Experience/Service

Academic Appointments

Associate Professor, Department of Stem Cell Transplantation, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2/2005-8/2011

Administrative Appointments/Responsibilities

Associate Program Director, Stem Cell Transplant Fellowship, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2008-present

Institutional Committee Activities

Quality Officer for Stem Cell Transplantation and Cellular Therapy, Ongoing Professional Practice Evaluation (OPPE) Committee, 10/2011-present
Alternate Member, Credentials Committee of the Medical Staff, 2011-present
Member, Computerized Provider Order Entry (CPOE) Steering Committee, 2010-present
Member, Faculty Senate, 2010-present
Member, Infection Control Committee, 2008-present
Member, Infection Control Core Group, 2008-present

Honors and Awards

2009-2011 Best Doctors in America, Best Doctors, Inc.

Selected Publications

Peer-Reviewed Original Research Articles
1. Joseph RW, Alousi A, Konda B, Komanduri K, Neumann J, Trevino C, Stolar K, Qazilbash M, Hosing C, Kebriaei P, Couriel DR, Champlin RE, Saliba R, Popat U. High incidence of vitamin D deficiency in patients undergoing allogeneic stem cell transplantation. Am J Hematol 86(11):954-6, 11/2011. e-Pub 9/21/2011. PMID: 21948087.
2. Ciurea SO, de Lima M, Giralt S, Saliba R, Bueso-Ramos C, Andersson BS, Hosing CM, Verstovsek S, Champlin RE, Popat U. Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation. Biol Blood Marrow Transplant 16(4):555-9, 4/2010. e-Pub 1/29/2010. PMID: 20005966.
3. Parmar S, Del Lima M, Zou Y, Patah PA, Liu P, Cano P, Rondon G, Pesoa S, de Padua Silva L, Qazilbash MH, Hosing C, Popat U, Kebriaei P, Shpall EJ, Giralt S, Champlin RE, Stastny P, Fernandez-Vina M. Donor-recipient mismatches in MHC class I chain-related gene A in unrelated donor transplantation lead to increased incidence of acute graft-versus-host disease. Blood 114(14):2884-7, 10/1/2009. e-Pub 8/4/2009. PMCID: PMC19654407.
4. Popat U, Saliba R, Thandi R, Hosing C, Qazilbash M, Anderlini P, Shpall E, McMannis J, Körbling M, Alousi A, Andersson B, Nieto Y, Kebriaei P, Khouri I, de Lima M, Weber D, Thomas S, Wang M, Jones R, Champlin R, Giralt S. Impairment of Filgrastim-Induced Stem Cell Mobilization after Prior Lenalidomide in Patients with Multiple Myeloma. Biol Blood Marrow Transplant 15(6):718-23, 6/2009. e-Pub 4/2009. PMCID: PMC19450756.
5. Hosing C, Saliba RM, Ahlawat S, Körbling M, Kebriaei P, Alousi A, De Lima M, Okoroji JG, McMannis J, Qazilbash M, Anderlini P, Giralt S, Champlin RE, Khouri I, Popat U. Poor hematopoietic stem cell mobilizers: A single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma. Am J Hematol 84(6):335-7, 6/2009. e-Pub 3/2009. PMCID: PMC19384931.
6. Champlin R, de Lima M, Kebriaei P, Rondon G, Fisher T, Jabbour E, Cortés JE, Kantarjian H, Anderlini P, Alousi A, Hosing C, Shpall E, Popat U, Qazilbash M, Andersson B, Giralt S. Nonmyeloablative allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era. Clin Lymphoma Myeloma 9 Suppl 3:S261-5, 2009. PMCID: PMC19778850.
7. Appel SH, Engelhardt JI, Henkel JS, Siklos L, Beers DR, Yen AA, Simpson EP, Luo Y, Carrum G, Heslop HE, Brenner MK, Popat U. Hematopoietic stem cell transplantation in patients with sporadic amyotrophic lateral sclerosis. Neurology 71(17):1326-34, 10/2008. PMCID: PMC18936424.
8. Tam CS, Nussenzveig RM, Popat U, Bueso-Ramos CE, Thomas DA, Cortes JA, Champlin RE, Ciurea SE, Manshouri T, Pierce SM, Kantarjian HM, Verstovsek S. The natural history and treatment outcome of blast phase BCR-ABL negative myeloproliferative neoplasms. Blood 112(5):1628-37, 9/1/2008. e-Pub 6/19/2008. PMCID: PMC18566326.
9. Nash RA, Stuve O, Bowen JD, Frohman EM, Griffith LM, Hutton GJ, Kraft GH, Popat U, Racke MK, Muraro PA. Autologous HSCT for advanced MS: is the glass half-empty or really half-full? Brain 131(Pt 2)(Pt 2):e89, 2/2008. e-Pub 9/2007. PMCID: PMC17908695.
10. Samuelson SJ, Popat U, Prchal JT. Marrow fibrosis does not account for circulating CD34+ cells in myelofibrosis with myeloid metaplasia. Haematologica 92(3 Suppl):ELT02, 3/2007. PMCID: PMC17405759.
11. Popat U, Heslop HE, Durett A, May R, Krance RA, Brenner MK, Carrum G. Outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation (RISCT) using antilymphocyte antibodies in patients with high-risk acute myeloid leukemia (AML). Bone Marrow Transplant 37(6):547-52, 3/2006. PMCID: PMC16462757.
12. Rousseau RF, Biagi E, Dutour A, Yvon ES, Brown MP, Lin T, Mei Z, Grilley B, Popek E, Heslop HE, Gee AP, Krance RA, Popat U, Carrum G, Margolin JF, Brenner MK. Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and allogeneic stem cell transplantation. Blood 107(4)(4):1332-1341, 2/15/2006. e-Pub 10/25/2005. PMCID: PMC16249392.
13. Popat U, Frost A, Liu E, Guan Y, Durette A, Reddy V, Prchal JT. High levels of circulating CD34 cells, dacrocytes, clonal hematopoiesis, and JAK2 mutation differentiate myelofibrosis with myeloid metaplasia from secondary myelofibrosis associated with pulmonary hypertension. Blood 107(9):3486-3488, 2006. PMCID: PMC16418333.
14. Lamba R, Carrum G, Myers GD, Bollard CM, Krance RA, Heslop HE, Brenner MK, Popat U. Cytomegalovirus (CMV) infections and CMV-specific cellular immune reconstitution following reduced intensity conditioning allogeneic stem cell transplantation with Alemtuzumab. Bone Marrow Transplant 36(9)(9):797-802, 11/2005. PMCID: PMC16151431.
15. Popat U, Frost A, Liu E, May R, Bag R, Reddy V, Prchal JT. New onset of myelofibrosis in association with pulmonary arterial hypertension. Ann Intern Med 143(6)(6):466-467, 9/20/2005. PMCID: PMC16172450.
16. Burt RK, Cohen B, Rose J, Petersen F, Oyama Y, Stefoski D, Katsamakis G, Carrier E, Kozak T, Muraro PA, Martin R, Hintzen R, Slavin S, Karussis D, Haggiag S, Voltarelli JC, Ellison GW, Jovanovic B, Popat U, McGuirk J, Statkute L, Verda L, Haas J, Arnold R. Hematopoietic stem cell transplantation for multiple sclerosis. Arch Neurol 62(6)(6):860-4, 6/2005. PMCID: PMC15956156.

Invited Articles
1. Popat U, Carrum G, Heslop HE. Haemopoietic stem cell transplantation for acute lymphoblastic leukaemia. Cancer Treat Rev 29(1):3-10, 2/2003. PMCID: PMC12633575.

Book Chapters
1. Popat U, Giralt S. Hematopoietic Cell Transplantation for Chronic Myeloid Leukemia. In: Contemporary Hematology, Stem Cell Transplantation for Hematoligic and other Disorders. Ed(s) R.J. Soiffer. Humana Press: Totowa, NJ, 2008.
2. Popat U, Giralt S. Hematopoietic cell transplantation for chronic myeloid leukemia and myelofibrosis. In: Chronic Myeloproliferative Disorders. Informa Press, 2008.
3. Rice L, Popat U. Non-Hodgkin's Lymphoma. In: Conn's Current Therapy 2008. Ed(s) HF Conn, D Martin, L Gunzel. Saunders-Elsevier: United Kingdom, 458-461, 2008. PMID: 978-1-4160-4435-2.
4. Fanale M, Dabaja B, Anderolini P, Popat U. 60 Years of Survival Outcomes at The University of Texas M. D. Anderson Cancer Center. In: The MD Anderson Manual of Medical Oncology. Submitted.

Grant & Contract Support

Title: Phase I Evaluation of the Safety and Efficacy of TXA127 (Angiotensin 17) to Enhance Engraftment in Adults Undergoing Double Cord Blood Transplantation
Funding Source: US Biotest, Inc.
Role: Principal Investigator
Duration: 3/3/2010 - 3/2/2015
 
Title: Allogeneic stem cell transplantation for myelofibrosis using reduced intensity busulfan and fludarabine conditioning.
Funding Source: Otsuka Pharmaceutical Company Ltd.
Role: Principal Investigator
Duration: 7/31/2009 - 7/31/2013
 
Title: Eltrombopag for post transplant thrombocytopenia
Funding Source: GlaxoSmithKline
Role: Principal Investigator
Duration: 4/1/2009 - 3/31/2014
 
Title: High dose immunosuppression and autologous transplantation for multiple sclerosis (HALT MS) study
Funding Source: NIH/NCI
Role: Principal Investigator-MDACC
Duration: 10/1/2006 - 2/28/2013

Last updated: 11/21/2011